HEBERPROT-P Cuban Medicine for the treatment of Diabetic Foot Ulcer

Cuban treatment for diabetic foot ulcer

Heberprot-P: A revolutionary therapy and hopeful. Heberprot-P is a novel Cuban medicine and Only Prescribed for Foot Ulcer Therapy diabetic drug (UPD) based on human growth factor recombinant (FCHrec.), through intralesional infiltration directly at the wound site.

The diabetic foot ulcer is an injury resulting of alterations in sensitivity, known as neuropathy peripheral and in present peripheral arthropathy in the irrigation of the arteries.

The more advanced the diabetes is in a patient, the This person is at greater risk of suffering from this injury.

HEBERPROT-P Cuban medication for the treatment of diabetic foot in Cuba

Factors that cause the development of diabetic foot

  1. Deformities of the foot or Charcot arthropathy
  2. Poor control of diabetes
  3. Neuropathy
  4. Arteriopathy
  5. Tobacco use

So any of these conditions can increase the risk of suffering from a diabetic foot ulcer and before The slightest trauma or wound makes healing difficult.

Treatment with Heberprot-P has benefited nearly 290,000 patients in twenty countries and demonstrates the possibility of a cure for the healing of complex wounds, ischemic ulcers and those resulting from diabetic foot, which increases the frequency of effective granulation formation in the injuries treated and therefore reduces the risks of amputation.

The drug, prepared by the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba, contains as active pharmaceutical ingredient to recombinant human epidermal growth factor, a peptide of 53 amino acids that when coupled to its receptor activates anabolic metabolism, promoting synthesis of amino acids and proteins, resulting in cell division. Heberprot-P is Considered unique and first of its kind, it is administered directly into the ulcerated tissues of the diabetic, generating accelerated granulation of the lesions.

Its basic principles are based on research carried out by the American scientist Stanley Cohen in the 60 years from observing the behavior in many species of animals of licking wounds, applying abundant saliva on openings in the skin, a trait that humans also do, especially when they injure their fingers due to burns or cuts.

From 2001 to 2005, clinical trials II and III were initiated and concluded in different centers of the national system. health of Cuba. In these scenarios, that about 86% of people with complex diabetic lesions who applied to treatment with Heberprot, did not suffer amputations.


Advantages of using Heberprot-P

Treatment withHeberprot-Paccelerates the healing of deep and complex ulcers therefore It can be used in ulcers of an ischemic and neuropathic nature larger than 20 centimeters.

It is the only one of its kind in the world, since treatments similar to this one are provided topically and directed at lesions that do not exceed 5 centimeters.

Reduces the risk of amputation in patients with diabetic foot ulcers.

Increases the quality of life of patients.

This treatment is the only one that has proven effective for grade 3 and 4 diabetic foot ulcers according to the Wagner scale, since other traditional methods on the market do not respond to ulcers ischemic or superiors at 20 square centimeters.

The results of Heberprot-P are successful against eight (8) types of injuries in patients with foot ulcers diabetic.

Contraindications of Heberprot-P

This drug is contraindicated in patients with a history of hypersensitivity to the product or any of its components.

In people who suffer from decompensated heart disease, diabetic coma or diabetic ketoacidosis.

Method of administration of Heberprot-P 75

Treatment with Heberprot-P for diabetic foot ulcers consists of administering the same at a rate of 75 µg, diluted in 5 mL of water for injection, three times a week, perilesionally and intralesional. HEBERPROT-P administrations will be continued until granulation is achieved. Complete recovery of the lesion, closure of the lesion by means of a graft or a maximum of 8 weeks of treatment is achieved. It's a injectable medication presented in the form of lyophilized in glass bulbs, administered parenterally, intralesionally and perilesional. (only under medical prescription and used with specialized personnel).

Its container contains 6R clear neutral borosilicate glass bulbs of class I hydrolytic quality, with a capacity of 5 mL, the Its active ingredient is recombinant human epidermal growth factor (FCEhrec); bromobutyl cap and flip-top cap.

Treatment withHEBERPROT-P is applied to people of any age, sex and race, with a diagnosis of diabetes mellitus regardless of the type of diabetes they have and the duration of the disease.

In the patients incorporated into the program we have observed a reduction in the amputation rate to less than five percent.


Each 5 mL bulb contains, depending on the dose:

Components Amount mg/5 mL of water
Recombinant human epidermal growth factor (HREF) 0.075 µg or 0.025 µg
Sucrose 15,000 mg
Dextran 40 5,000 mg
Disodium hydrogen phosphate 0.454 mg
Sodium dihydrogen phosphate dihydrate 1,061 mg
Water for injection 5 mL

Note: FCEhrec is a peptide that stimulates cell proliferation and healing.

Treatment Price and Program

All information you send to us will be used only for medical proposes.
Please fill our validation code.


Do not hesitate to contact us for any concern


Medical Services Providers